Key facts
- It has raised $7.5M.
- Notable investors include Creative Destruction Lab, University of Toronto, Scale Good Fund, Scale Up Canada, Aubrey Rankin — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Nanostics
- ·The full record, as it builds
Funding rounds
No funding rounds for Nanostics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Nanostics
Operator of a precision health technology platform designed to improve early cancer detection. The company offers an AI-enabled diagnostic product that integrates machine learning with biomarker analysis, enabling partner laboratories to enhance prostate cancer screening accuracy and reduce unnecessary biopsies.
- Sector
- Healthcare
- HQ
- Edmonton, Canada
- Founded
- 2017
- Employees
- 14
- Website
- nanosticsdx.com/
- Ownership
- Privately Held (backing)
Nanostics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nanostics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nanostics in its N-PORT filings yet. We sweep new filings monthly.